VB - Vanguard Small-Cap ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
142.74
-0.03 (-0.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close142.77
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume518,512
Net Assets79.84B
NAV141.29
PE Ratio (TTM)N/A
Yield1.39%
YTD Return10.58%
Beta (3y)1.05
Expense Ratio (net)0.06%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • Hot Areas of Last Week and Their ETFs
    Zacks29 days ago

    Hot Areas of Last Week and Their ETFs

    Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.

  • Market Realistlast month

    Nuplazid Sees Increasing Physician Intent to Prescribe in 2017

    Acadia Pharmaceuticals' (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.

  • Morningstar2 months ago

    Small Caps: The Easy Game for Active Managers?

    The odds may be better for small-cap managers, but they're still long.

  • Here's Why Small Cap ETFs Are Underperforming
    Zacks2 months ago

    Here's Why Small Cap ETFs Are Underperforming

    U.S. small cap ETFs suffer on account of growing uncertainty around Trump's pro-growth policies.

  • Zacks2 months ago

    U.S. Small Business Confidence Up in July: ETFs in Focus

    U.S. small business activity improves in July; beats estimates.

  • Market Realist3 months ago

    Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017

    Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.

  • Market Realist3 months ago

    Where Abiomed Plans to Expand Impella CP’s Label

    About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.

  • Market Realist4 months ago

    These Are Align Technologies Key Demand Drivers in North America

    In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).

  • What Happened in the Stock Market Today
    Motley Fool5 months ago

    What Happened in the Stock Market Today

    Palo Alto Networks leaped, Hewlett Packard Enterprise fell, and major market averages started June on a positive note.

  • ETF Basics: How to Choose the Right Exchange-Traded Fund for You
    Motley Fool5 months ago

    ETF Basics: How to Choose the Right Exchange-Traded Fund for You

    Here's how exchange-traded funds work, why they benefit retail investors, and how to pick the right ETFs for your portfolio.

  • Market Realist5 months ago

    Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017

    On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.

  • So Far, So Good for Small-Cap Earnings
    Harvest Exchange5 months ago

    So Far, So Good for Small-Cap Earnings

    With arrival of spring comes first-quarter earnings announcements throughout the stock market. Large-cap companies generally report a little earlier, business results are better than 1Q's GDP might imply, and the news so far for both small- and ...

  • Harvest Exchange6 months ago

    Small Cap Owning Large Cap, Mass Hysteria!

    By Roger Nusbaum, AdvisorShares ETF Strategist The title of this post is a play on the bit in the movie Stripes when Bill Murray talks about dogs and cats living together. You probably heard about the niche ETF (naming names is difficult for ...

  • Market Realist6 months ago

    Behind Exelixis’s Successful Commercial Launch of Cabometyx in 2016

    Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.

  • Harvest Exchange6 months ago

    Small caps looking for a catalyst

    U.S. stocks are off to another stellar year. Look below the surface, however, and the rally has had a somewhat unusual flavor. Some of the better performing stocks are in the more defensive industries, such as utilities and health care, while small ...

  • Swedroe: Following Up On 2017’s ‘Sure Things’
    ETF.com6 months ago

    Swedroe: Following Up On 2017’s ‘Sure Things’

    At the start of each year, I put together a list of predictions gurus make for the upcoming year—sort of a consensus of “sure things.” We keep track of the sure things with a review at the end of each quarter. With March behind us, it’s time for our first review. As is our practice, we give a positive score for a forecast that came true, a negative score for one that was wrong and a zero for one that was basically a tie.

  • Benzinga6 months ago

    Year Of The Stock Picker? Think Again

    Rewind back to late 2016 and early 2017 and it is easy to find a slew of articles speculating that 2017 would be the year of stock pickers and that active managers would bounce back against passive products, ...

  • The ‘Stock Picker’s Market’ That Wasn’t
    ETF.com6 months ago

    The ‘Stock Picker’s Market’ That Wasn’t

    Todd Rosenbluth is director of ETF and mutual fund research at CFRA. While 2017 was supposedly set up as a U.S. stock pickers’ market—with a new president, a Federal Reserve poised to raise rates and expectations of higher stock dispersion creating opportunities to spot winners—it is not looking good so far. Just 31% of large-cap core mutual funds ended the first quarter beating the S&P 500 index’s total return, while 33% of small-cap core funds bested the Russell 2000 Index.

  • Small is Beautiful
    Harvest Exchange6 months ago

    Small is Beautiful

    U.S. smaller companies have endured seven lean years, but are they poised for a comeback? The influential German economist E.F. Schumacher coined the phrase “small is beautiful” back in 1973 in his best-selling book about the relation between mankind ...

  • Small cap vs large cap: how valuations compare
    Harvest Exchange7 months ago

    Small cap vs large cap: how valuations compare

    Smaller company shares have outperformed over time. Global “small caps” have returned almost three times as much as large companies over the last 16 years. Since March 2001 the MSCI Global Small Cap Index has returned 317%, including dividends, ...

  • 5 Top Funds for Your 401(k)
    Motley Fool7 months ago

    5 Top Funds for Your 401(k)

    While there's no one-size-fits-all solution, these five funds -- with very low fees -- are a great place to start.

  • ETF.com7 months ago

    Swedroe: Private Equity Adds Risk, Little Return

    The term “private equity” is used to describe various types (e.g., buyout funds and venture capital funds) of privately placed (nonpublicly traded) investments. Even though buyout (BO) funds and venture capital (VC) funds have similar organizational and compensation structures, they are distinguished by the types of investments they make and the way those investments are financed.

  • Zacks7 months ago

    Small Cap ETFs: Leaders or Laggards

    Economic expansion prompted by Trump's win and Fed's monetary policy are the two major driving forces of the small cap stocks performance.

  • Why Small Cap ETFs Are Underperforming
    ETF.com7 months ago

    Why Small Cap ETFs Are Underperforming

    Small-cap ETFs were all the rage in 2016, with some of the largest funds in the segment delivering roughly twice the gains of U.S. large-cap ETFs in one year. But so far in 2017, small-caps have done very little. They’re lagging their large-cap counterparts significantly, and fostering at least a little hesitation among some investors as to what lies ahead for the stock market.